Watch for continued U.S. launch trajectory in acquired HO, initiation of pivotal Phase 3 trials for bivamelagon by year-end 2026, and European country-level launches beginning in 2027. The $750M loan facility provides significant financial flexibility for pipeline advancement.
Drug in focus
RYTM drug pipeline →IMCIVREE
▲ Bullish Named in this press release- Impact
- Not rated
- Phase
- Not stated
- Time to market
- Not stated
- Next catalyst
- None dated
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $86.44entry
- T+1 · 13d ago +28.04%α +26.39% · $110.68
- T+5 · 7d ago +31.83%α +32.41% · $113.95
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals reported Q3 2026 IMCIVREE revenue of $92.1M, a 29% sequential increase and 80% YoY growth, beating the $84.6M consensus. Net loss per share of $(0.61) was narrower than the consensus estimate of $(0.74). The company also secured a $750M term loan facility and amended its bivamelagon license with LG Chem, reducing the royalty to 1% in exchange for $350M in fixed payments.
Key Financial Metrics
Key Facts
- Q3 2026 IMCIVREE net product revenue of $92.1M, up 29% sequentially and 80% YoY from $51.3M
- Revenue beat consensus of $84.6M by 8.9%
- GAAP net loss per share of $(0.61) vs consensus estimate of $(0.74)
- Over 700 patient start forms for IMCIVREE in acquired HO from more than 500 prescribers as of Sep 30, 2026
- Entered into a five-year term loan facility for up to $750M, with $250M initial draw
- Amended LG Chem bivamelagon license: $350M fixed payments over four years in exchange for reducing royalty to 1%
- Cash, cash equivalents and short-term investments of $320.9M as of Sep 30, 2026 (excluding the $250M loan draw and $70M LG Chem payment)
- Company expects cash to fund operations for at least 24 months
- Non-GAAP operating expense guidance for FY2026: $360M-$380M
Financial Impact
Revenue beat of $7.5M (8.9%) vs consensus; net loss narrowed by $0.13/share vs consensus; $250M initial draw on $750M loan facility adds liquidity
Risk Factors
- Dependence on continued commercial success of IMCIVREE in acquired HO, a recently approved indication
- $350M fixed payment obligation to LG Chem over four years creates significant cash outflow
- R&D and SG&A expenses are growing rapidly (R&D +14% YoY, SG&A +27% YoY), pressuring path to profitability
- Clinical and regulatory risks for bivamelagon and RM-718 pipeline candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394041 |
Track record
26 reports on RYTM
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Viewing Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers